HER2 overexpression predicts pCR. Factors associated with a higher pCR rate included grade 3 histology, hormonal receptor negativity, dual anti-HER2 therapy, and HER2 protein overexpression.

HER-2 overexpression, a predictive marker of tumour aggressiveness and responsiveness to therapy, occurs in 20–30% of breast cancer. Although breast cancer is a heterogeneous disease, HER-2 ...

Because HER2 status is important in understanding how aggressive a tumor might be—and how best to treat it—testing should be performed on the biopsy or surgery sample of all newly diagnosed ...

Our study demonstrates that HER2 overexpression is associated with a higher sensitivity to HDCT (conversion rate 87.5% in HER2-positive patients vs 37% in HER2-negative patients).

HER-2/neu Overexpression and Response to Oophorectomy Plus Tamoxifen Adjuvant Therapy in Estrogen Receptor-Positive Premenopausal Women With Operable Breast Cancer Purpose: Human epidermal growth ...

A HER2-positive status reflects breast cancer cells with extra copies of the HER2 gene, ... protein present because HER2 assays are semiquantitative and were optimized to detect HER2 overexpression.

Access free, up-to-date clinical references about molecular testing and biomarkers for HER2-positive breast cancer. Healio's Clinical Guidance content provides valuable insights for physicians.

Kanwal Raghav, MD, MBBS: We don’t have a lot of data regarding the comparison of biomarker testing between the academic and community settings, least of all for HER2 amplification, knowing that ...

PURPOSE: To determine the frequency of Her-2 overexpression in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site. PATIENTS AND METHODS: ...

The HER2 overexpression group had a significantly lower 5-year recurrence-free survival (RFS) rate compared with the low HER2 group (16.5% vs 68.0%), Dr Yao’s team reported in European Urology ...

HER2 (also known as ERBB2) amplification or overexpression occurs in a relatively small proportion of metastatic colorectal cancer (mCRC) cases 1; nevertheless, early identification of patients ...